Highlight
1. Tirzepatide at a low dose of 5 mg weekly significantly increased insulin sensitivity measured by glucose infusion rate (GIR) within 12 weeks.
2. HbA1c and body weight notably decreased alongside reductions in fat mass and glucagon levels.
3. Improvement in insulin sensitivity occurred independent of weight loss, suggesting direct metabolic effects.
4. No significant correlations were found between GIR changes and typical metabolic markers, indicating a complex mechanism of action.
